BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 30
• 31

• Press Releases

  Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update

  August 30, 2026

   · 

  4 min read
• Press Releases

  Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 28, 2026

  August 30, 2026

   · 

  2 min read
• Press Releases

  Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update

  August 30, 2026

   · 

  9 min read
• Press Releases

  Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

  August 30, 2026

   · 

  14 min read
• Press Releases

  Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera

  August 30, 2026

   · 

  11 min read
• Press Releases

  Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

  August 30, 2026

   · 

  9 min read
• Press Releases

  NATURE Randomized Controlled Trial Meets Primary Endpoint Evaluating enVast-Assisted Mechanical Thrombectomy in Large-Thrombus STEMI

  August 30, 2026

   · 

  5 min read
• Press Releases

  Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026

  August 30, 2026

   · 

  17 min read
• Press Releases

  AskBio Presents Baseline Characteristics from Phase 2 Heart Failure Gene Therapy Trial of Umiposgene Parvec (AB-1002) at European Society of Cardiology Congress

  August 30, 2026

   · 

  9 min read
• Press Releases

  Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

  August 30, 2026

   · 

  19 min read